Humacyte says FDA accepts IND for first-in-human CTEV CABG study
HUMA•FDA accepts IND for first-in-human study
Humacyte said the FDA has accepted its investigational new drug application for a first-in-human study of its coronary tissue engineered vessel in coronary artery bypass grafting (CABG).
The phase 2a trial is set to start this quarter in 10 adult patients. The primary patency check will be at two months, with follow-up lasting up to three years.
